Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 10/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962405 | 1.00 | ACHE (0.58) | ACHEDRD2DRD3HTR1ACHRM2 | |
| SCHEMBL30563633 | 1.00 | ACHE (0.58) | ACHEDRD2DRD3HTR1ACHRM2 | |
| SCHEMBL598626 | 1.00 | ACHE (0.58) | ACHEDRD2DRD3HTR1ACHRM2 | |
| Hydrochloric Acid SCHEMBL659578 | 0.98 | ACHE (0.61) | ACHEDRD2DRD3HTR1ACHRM2 | |
| Hydrochloric Acid SCHEMBL31186909 | 0.98 | ACHE (0.61) | ACHEDRD2DRD3HTR1ACHRM2 | |
| Hydrochloric Acid SCHEMBL30563614 | 0.98 | ACHE (0.61) | ACHEDRD2DRD3HTR1ACHRM2 | |
| Hydrochloric Acid SCHEMBL26962688 | 0.98 | ACHE (0.61) | ACHEDRD2DRD3HTR1ACHRM2 | |
| SCHEMBL266635 | 0.90 | DRD2 (0.50) | ACHEDRD2DRD3HTR1A | |
| SCHEMBL8666712 | 0.81 | DRD2 (0.57) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL8670289 | 0.80 | DRD2 (0.56) | DRD2DRD3HTR1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1535902-B1 | Aminoindan derivatives | TEVA PHARMA (IL) | 2007-11-07 | — | — | EP | disclosed |
| US-RE39616-E1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-08 | — | — | US | disclosed |
| EP-1535902-A1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-06-01 | — | — | EP | disclosed |
| EP-0966435-B1 | AMINOINDAN DERIVATIVES | TEVA PHARMA (IL) | 2005-04-06 | — | — | EP | disclosed |
| US-6538025-B2 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-25 | — | — | US | disclosed |
| US-20020188020-A1 | Aminoindan derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2002-12-12 | — | — | US | disclosed |
| US-6462222-B1 | TREATMENT OF DEMENTIAS OF THE ALZHEIMER TYPE AND MEMORY DISORDERS AS WELL AS ATTENTION DEFECIT DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-10-08 | — | — | US | disclosed |
| US-6303650-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE OR DEMENTIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | ACHE 953/4885DRD2 2088/4885DRD3 2825/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | ACHE 479/4885DRD2 3950/4885DRD3 4031/4885 |
| US-20020188020-A1 | Aminoindan derivatives | SNCA, HTR1A, HTR1D | ACHE 58/4885DRD2 18/4885DRD3 9/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | ACHE 59/4885DRD2 3792/4885DRD3 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.